Elizabeth Swisher, MD of University of Washington Medical Center gives an overview of a second presentation that discussed the ARIEL2 Trial at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. From the presentation, the data concluded that the patients who developed platinum-resistance were less likely to respond to the drug. She argues clinicians need to introduce the drug earlier in treatment so patients don’t develop resistance.
ARIEL2 Trial: Patients Who Developed Platinum-Resistance Less Likely to Respond
